world
Class-Action Lawsuit Targets Three Major U.S. Cannabis Firms on Advertising Claims
A class-action lawsuit accuses three of America's largest cannabis companies of falsely advertising their products as treatments for mental health and pain disorders. Filed in federal court in Illinois on behalf of consumers in 12 states, the suit seeks accountability for misrepresentations and warnings about cannabis dangers. It could expand to include millions of plaintiffs.
The Free PressAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Three of America's largest cannabis companies face a class-action lawsuit accusing them of systematically advertising their products as medicine capable of treating mental health, pain, and other disorders. The suit, filed on Monday in federal court in Illinois, represents consumers in 12 states.
The Free Press reported that the action alleges the companies know science does not support their health claims but continue making them, and that the products could even worsen the conditions they claim to treat.
Patrick Kenneally, the plaintiffs' lead attorney, said in an interview that the lawsuit's aims are to hold the cannabis industry accountable for years of misrepresentation of their products' health benefits and to force them to warn consumers about the well-known, obvious, and scientifically validated dangers of cannabis.
The Free Press described the suit's goals as twofold, emphasizing accountability and consumer warnings. Between possible civil penalties, punitive damages, and allegations that each company functions as an organized criminal enterprise, the stakes are enormous, according to the reporting.
The lawsuit could eventually include millions of plaintiffs, expanding beyond the initial group from 12 states. The Free Press noted that the companies are accused of going beyond implied medical endorsements in their marketing. Kenneally's statement highlighted the systematic nature of the alleged advertising practices, tying them to broader industry patterns of overstating benefits without scientific backing.
